Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "Serum-Institute-of-India"

44 News Found

Indian vaccine players to garner Rs. 70,599 Cr in 2021
News | April 30, 2021

Indian vaccine players to garner Rs. 70,599 Cr in 2021

Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong

Sputnik V needs to be priced at par with Covishield & Covaxin
News | April 23, 2021

Sputnik V needs to be priced at par with Covishield & Covaxin

Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply

Serum not contracted for complete production of COVID vaccine to centre
News | April 23, 2021

Serum not contracted for complete production of COVID vaccine to centre

These media reports are based on incorrect facts and are without any basis.

Indian Pharma market to grow to US$ 130 bn by 2030: Gowda
News | February 11, 2021

Indian Pharma market to grow to US$ 130 bn by 2030: Gowda

The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.

Latest Stories

Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets

Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke

FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging